tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kaveri Pohlman, 11 are a BUY (84.62%), 2 are a HOLD (15.38%).
Analyst Kaveri Pohlman works at BTIG with a stock forecast success ratio of 18.75% fulfilled within 40.63 days on average.
Kaveri Pohlman’s has documented 24 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NUVB, Nuvation Bio at 26-Mar-2024.
Analyst best performing recommendations are on CMPI (CHECKMATE PHARMACEUTICALS).
The best stock recommendation documented was for CMPI (CHECKMATE PHARMACEUTICALS) at 3/30/2022. The price target of $9 was fulfilled within 20 days with a profit of $5.78 (179.5%) receiving and performance score of 89.75.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
3
$0.94 (45.63%)
2
5 months 10 days ago
3/8 (37.5%)
$1.75 (140.00%)
119
Hold
3.3
$1.24 (60.19%)
3.19
5 months 10 days ago
1/9 (11.11%)
$2.05 (164.00%)
56
Hold
2
$-0.06 (-2.91%)
4
1 years 21 days ago
1/6 (16.67%)
$0.48 (31.58%)
336
Sell
12
1 years 5 months 8 days ago
0/2 (0%)
$7.4 (160.87%)
Hold
1.75
$-0.31 (-15.05%)
1.5
1 years 8 months 13 days ago
2/5 (40%)
$0.09 (5.42%)
59
Which stock is Kaveri Pohlman is most bullish on?
Which stock is Kaveri Pohlman is most reserved on?
What Year was the first public recommendation made by Kaveri Pohlman?
